We've heard about these presentations, but have yet to actually see them.
Optometrists are increasingly involved in recommending—and even performing—PIs. Here, an Oklahoma OD walks us through the procedure.
This patient returned after uncomplicated cataract surgery with an unexpected "correction" to his glaucoma. How did this happen?
Stem Cells to Reverse AMD Damage
Here, we review diagnostic strategies for a wide variety of optic nerve irregularities that may be observed in clinical practice.
Patients could measure their own IOP using a smartphone app.
Researchers have found acute angle-closure glaucoma is an inflammatory disease.
How do you respond to the glaucoma patient’s question: ‘Can you see Alzheimer’s in my eyes?’
Patients with pseudoexfoliative glaucoma often require a more thorough diagnostic work-up and earlier intervention than those with POAG. So how do these conditions differ, and why?
This uveitis patient is also a steroid responder. Which problem do you tackle first?
Is there a role for iridotomy when managing patients with pigmentary glaucoma?
As the aging population doubles and minority groups skyrocket, we face increased challenges in tailoring our glaucoma care to each patient.
Our success in managing glaucoma hinges on our ability to recognize—and make sense of—both structural and functional changes.
Patient presents for a glaucoma consult with mixed findings. Does her macula give us a hint?
Managing a steroid responder is rather straightforward.
24-Hour IOP monitoring: A reality?
This patient’s IOP is slowly on the rise, despite topical medication.
Glaucoma experts shared and absorbed new insights in research and patient care.
MIGS procedures can safely and effectively reduce IOP in patients.
Rho-kinase inhibitors offer a new path to lower IOP.
Unique challenges and unanswered questions raised by this apparent anomaly.
A 72-year-old suspect apparently converts to glaucoma—at least according to certain tests. So, do you begin treatment now?
From corneal transplant outcomes to the eagerly-awaited results of AREDS2.
Fresh data on new structural metrics, visual fields, blood flow and the latest glaucoma drug.
Same patient, same nerve. Different objective test results? Certainly!
Were there telltale risk factors that may have resulted in earlier treatment for this patient?
Understanding visual fields is not black and white—not even shades of gray.
You don’t want to deny your patients, but you also don’t want to hand out samples like candy.
Is there a link between pseudotumor cerebri and a family history of glaucoma?
A 63-year-old glaucoma suspect presents with a disc hemorrhage.
Should we offer laser trabeculoplasty instead of a prostaglandin?
Despite relatively normal findings, our 70-year-old patient was on multiple glaucoma medications.
Xanthophylls may not only protect the retina, but also enhance its function.
New insights on topical therapy, prevention, structure, function and diagnostic technologies.
What every O.D. needs to know about this increasingly popular procedure.
A longstanding patient with PXG in one eye wonders how she ‘got’ it.
An ocular hypertensive patient who is being treated for a dermatologic issue is a